Abstract
SARS-CoV-2 RNA shedding in stool enabled wastewater surveillance for the genetic material of the virus. With the emergence of novel variants of concern and interest it becomes increasingly important to track arrival and spread of these variants. However, most current approaches rely on the manually curated lists of mutations phenotypically associated with the variants of concern. The resulting data has many overlaps between distinct variants leading to less specific characterization of complex sample mixtures that result from wastewater monitoring. In our work we propose a simple and specific method for characterization of wastewater samples by introducing the concept of quasi-unique mutations. Our approach is data driven and results in earlier detection and higher resolution of variants of concern emergence patterns in wastewater data.
Importance Wastewater-based epidemiology has emerged as a powerful tool for public health response to the SARS-CoV-2 pandemic. As wastewater is a pooled, community sample of all persons contributing to the waste stream, there are several challenges in using sequencing information from wastewater samples to detect variants. Wastewater typically will consist of fragmented genomes from multiple, circulating variants. While it is straightforward to call the mutations present in a wastewater sample, it is more challenging to call the presence of variants that are defined by a set of characteristic mutations, particularly when mutations are shared among many circulating variants. Hence, we present a novel approach for screening for variants of concern in wastewater. Our computational approach introduces the concept of a “quasi-unique mutation” corresponding to a given PANGO lineage. We show that our method enables detection of the emergence of variants of concern in communities, providing a new approach for wastewater-based epidemiology of SARS-CoV-2.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Houston Health Department. E.L. and L.B.S. were supported in part by the National Science Foundation (CBET 2029025), and seed funds from Rice University. T.T. and N.S. were supported in part by C3.ai DTI and P01-AI152999 NIH awards. K.B.E. was supported in part by National Institute of Environmental Health Sciences, R01ES028819.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No IRB required for the work described.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵# These authors share senior authorship
Data Availability
Data is available upon request.
